Brest

• A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended
  2023-509406-30-00 10 2022-01-24 Patients with HER2-overexpressing advanced or metastatic gastric or ga
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia … Ended
  2024-510744-31-00 5 2021-10-06 Giant cell arteritis (GCA)
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma
• CAIRE : COMBINING EPIGENETIC AND IMMUNE THERAPY TO BEAT CANCER Ended
  2023-509501-72-00 4 2021-07-05 Adult participants with metastatic or unresectable locally advanced so
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local … Ended
  2024-513870-23-00 5 2021-06-28 Locally Advanced or Metastatic Unresectable Urothelial Cancer
• IMPACT-CTEPH Ended
  2024-513672-17-00 4 2021-06-14 Inoperable Chronic thromboembolic pulmonary hyperTension
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A multicenter, prospective, randomized, placebo-controlled, double-blind, multi-arm, multi-stage clinical trial of Ivabradine for heart Rate … Ended
  2024-515019-22-00 5 2021-02-26 Septic shock
• EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a … Ended
  2024-514344-82-00 5 2021-02-18 patients with acute respiratory failure from undetermined etiology
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• Adjunctive DobutAmine in sePtic cardiomyopathy with Tissue hypoperfusion: a randomized controlled multi-center trial Ended
  2024-517839-50-00 11 2020-09-20 sepsis
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage … Ended
  2024-516201-23-00 4 2019-08-26 Lung Cancer, NSCLC
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neck Ended
  2024-513977-31-00 4 2019-07-17 Untreated squamous cell carcinoma of the head and neck
• Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended
  2024-517309-95-00 5 2019-06-19 -Peripheral neuropathy clinically defined: *Pure sensitive (lymph node
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum) Ended
  2024-512855-19-00 4 2019-04-30 Rectal adenocarcinoma
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma

Showing 457–480 of 490 trials